Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland Receive Planview Vision Awards
13.11.2019 19:01:00 EET | Business Wire | Press release
Over 700 attendees came together at Planview Horizons 2019 to connect, collaborate, and celebrate with their industry peers. This year, Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland were the recipients of Planview Vision Awards for transformational leadership and excellence.
“There are many remarkable business transformation journeys that our customers have undertaken leveraging Planview solutions,” said Marc Cannon, Planview chief customer officer. “We were honored at this year’s Planview Horizons to celebrate these six visionary organizations for their commitment to, and success in, achieving their strategic goals.”
Advance Auto Parts
To address the industry trends around increased use of ridesharing, electric cars, and autonomous vehicles, a few “hidden innovators” at Advance Auto Parts set out to generate and collaborate on new ideas that would disrupt the market and delight their customers. With Planview Spigit™, Advance Auto Parts is successfully driving a culture of innovation.
Blue Cross NC
Blue Cross NC is shifting to a product-centric approach, utilizing continuous planning and delivery to achieve their mission: improving the health and well-being of customers. By leveraging Planview solutions, the organization is moving toward transformation, igniting innovation, and driving agility for relentless execution, all essential to realizing their strategy and vision.
Emory Healthcare
Being unable to forecast three weeks out or answer executives’ questions created an opportunity for Emory Healthcare to implement a solution for work intake, workflow management, and collaboration. The combination of Planview PPM Pro™ and Planview LeanKit™ allows Emory Healthcare to tell a collective story of status, flow, delivery, and alignment to strategy.
Johnsonville
Johnsonville recognizes that no matter how teams work, all goals and processes need to be measurable and reportable to ultimately deliver results. Johnsonville utilizes Planview Enterprise One™ and Planview Projectplace™ across the organization to enable collaboration that drives efficiency and innovation in making great tasting, high-quality products craved around the globe.
Parkview Health
Leveraging strategic work intake to prioritize projects within Planview PPM Pro has given Parkview Health the ability to identify investments that align with the organization’s strategic intent. Working with senior leaders, the EPPM team has helped prioritize and optimize capital spend. In addition, Parkview Health has seen increased productivity and collaboration with the rollout of Planview Projectplace across multiple business lines.
Royal Bank of Scotland
Royal Bank of Scotland (RBS) is shifting its approach toward investments and faster delivery to become a Lean enterprise by using the SAFe model. RBS evolved its use of Planview solutions to move from standard PPM processes and frameworks to embrace an agility-centric mindset, establish programs as key strategic vehicles to achieve outcomes and benefits, and discover new ways of working to realize a scaled Agile transformation. View this webcast to learn more.
About Planview
There is a bold new way of working, where every individual and team can move seamlessly from strategy to successful delivery – every day. Planview makes it possible. We provide the industry’s best and most comprehensive solutions designed for strategic planning, portfolio and resource management, Lean and Agile delivery, product portfolio management, capability and technology management, innovation management, and collaborative work management. Imagine realizing Agile at scale, creating a culture of innovation, and making the product shift. You are a change agent. So are we. For more information, visit www.planview.com.
Planview® and Planview Horizons® are registered trademarks of Planview, Inc.
All other trademarks listed herein are owned by their respective companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005594/en/
Contact information
Planview
Karoline McLaughlin
kmclaughlin@planview.com
+1 512 596 3493
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom